Skip to main content
Premium Trial:

Request an Annual Quote

Research Consortium to Use GeneGo s MetaCore in Nutrigenomic Research

NEW YORK, Nov. 14 (GenomeWeb News) - GeneGo expanded its partnership with European research group TNO into a consortium of other nutrigenomics researchers, the company announced today.


The consortium will consist of 23 universities and research institutes active in nutrigenomics research, including employees from TNO, an independent nutrition research institute, the Dutch Nutrigenomics Consortium, and the European Nutrigenomics Organization.


Consortium members will use GeneGo's MetaCore 3.0 software to build metabolic/signaling networks with experimental data and to share experiments and results with each other.


"Upon our request, GeneGo has extended its software with a metabolomics parser, allowing simultaneous visualization of gene expression and metabolite concentration in the same pathways," Ben van Ommen, responsible for the nutrigenomics activities at TNO and director of NuGO, said in a statement.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.